Characteristics | OASIS (n=161)* | GLAS (n=264)* | P values | Overall (n=425)* |
Age (years) | 49.1 (11.7) | 42.7 (11.9) | <0.001 | 45.2 (12.2) |
Male sex | 112 (69.6%) | 179 (67.8%) | 0.704 | 291 (68.5%) |
Smoking—yes | 41/116 (35.3%) | 88/229 (38.4%) | 0.576 | 129/345 (37.4%) |
BMI | 26.5 (4.9) | 26.6 (4.3) | 0.817 | 26.5 (4.5) |
Symptom duration | 26.0 (11.5) | 17.2 (11.3) | <0.001 | 20.6 (12.2) |
CRP (mg/L) | 12.3 (17.0) | 18.0 (18.3) | 0.002 | 16.0 (18.1) |
HLA-B27-positive | 129/156 (82.7%) | 204/257 (79.4%) | 0.409 | 333/413 (80.6%) |
Presence of (bridging) syndesmophytes | 74/109 (67.9%) | 107/197 (54.3%) | 0.021 | 181/306 (59.2%) |
Start anti-TNF-α treatment | 1/154 (0.6%) | 256/262 (97.7%) | <0.001 | 257/416 (61.8%) |
BASDAI (0–10 | 3.3 (2.3) | 6.1 (1.7) | <0.001 | 5.1 (2.3) |
BASFI (0–10 | 3.6 (2.7) | 5.6 (2.2) | <0.001 | 4.9 (2.6) |
Patient GDA (0–10) | 3.4 (2.7) | 6.7 (1.9) | <0.001 | 5.5 (2.7) |
Physician GDA (0–10) | 2.0 (1.6) | 4.7 (2.2) | <0.001 | 3.8 (2.4) |
ASDAS-CRP | 2.5 (1.1) | 3.8 (0.8) | <0.001 | 3.3 (1.1) |
ASQoL (0–18) | 5.8 (4.7) | 10.0 (4.1) | <0.001 | 8.7 (4.7) |
Attrition ASQoL (≥2 missing final measures) | 42 (26.1%) | 57 (21.6%) | 0.288 | 99 (23.3%) |
Attrition ASDAS-CRP (≥2 missing final measures) | 62 (28.5%) | 56 (21.2%) | <0.001 | 118 (27.8%) |
Values represent mean (SD) or number (%).
*Number of patients per group, unless otherwise stated due to missing values.
anti-TNF-α treatment, antitumour necrosis factor α treatment; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score—C reactive protein; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, body mass index; CRP, C reactive protein; GDA, Global Disease Activity Score; GLAS, Groningen Leeuwarden Ankylosing Spondylitis; HLA-B27, Human Leucocyte Antigen B27; OASIS, Outcome in Ankylosing Spondylitis International Study.